Literature DB >> 19962949

Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection.

Lauriane Goldwirt1, Aurélie Barrail-Tran, Maria Da Cruz, Anne-Marie Taburet, Valérie Furlan.   

Abstract

A precise and accurate high-performance liquid chromatography (HPLC) method with photodiode array detection has been developed and validated for raltegravir, a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI). Plasma (300 microL) was extracted with dichloromethane/hexane 50:50 (v/v) after addition of the internal standard, 6,7-dimethyl-2,3-di(2-pyridyl) quinoxaline. The compounds were separated using a dC18 column and detected with ultraviolet detection at 320 nm. The limit of quantification was 10 ng/mL for raltegravir. The method was linear and validated over a concentration range of 0-10,000 ng/mL. The intra-day precision ranged from 3.1 to 12.3%, while the intra-day accuracy ranged from -15.0 to -0.5%, the inter-day precision and accuracy were less than 7%. The mean recovery was 76.8%. Application to clinical samples taken from patients treated with raltegravir indicated that the method is suitable for measuring plasma concentrations of raltegravir in pharmacokinetic studies of clinical trials. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962949     DOI: 10.1016/j.jchromb.2009.10.029

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.

Authors:  Caroline Barau; Constance Delaugerre; Joséphine Braun; Nathalie de Castro; Valérie Furlan; Isabelle Charreau; Laurence Gérard; Caroline Lascoux-Combe; Jean-Michel Molina; Anne-Marie Taburet
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

2.  Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.

Authors:  Sébastien Gallien; Constance Delaugerre; Isabelle Charreau; Joséphine Braun; Thomas Boulet; Aurélie Barrail-Tran; Nathalie de Castro; Jean-Michel Molina; Daniel R Kuritzkes
Journal:  AIDS       Date:  2011-03-13       Impact factor: 4.177

3.  Selective and rapid determination of raltegravir in human plasma by liquid chromatography-tandem mass spectrometry in the negative ionization mode.

Authors:  Ajay Gupta; Swati Guttikar; Priyanka A Shah; Gajendra Solanki; Pranav S Shrivastav; Mallika Sanyal
Journal:  J Pharm Anal       Date:  2014-10-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.